Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor

Clinical Cancer Research

Volumn 16, Issue 7, 2010, Pages 2036-2045

  Williams, Richard D ^a   Al Saadi, Reem ^a   Chagtai, Tasnim ^a   Popov, Sergey ^a   Messahel, Boo ^a   Sebire, Neil ^b   Gessler, Manfred ^c   Wegert, Jenny ^c   Graf, Norbert ^d   Leuschner, Ivo ^e   Hubank, Mike ^b   Jones, Chris ^a   Vujanic, Gordan ^f   Pritchard Jones, Kathy ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

UBIQUITIN PROTEIN LIGASE E3;

ARTICLE; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; FBXW7 GENE; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MYCN GENE; NEPHROBLASTOMA; ONCOGENE; PRIORITY JOURNAL;

CELL CYCLE PROTEINS; CHILD; CHROMOSOMES, HUMAN, PAIR 2; F-BOX PROTEINS; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENES, WILMS TUMOR; HUMANS; KIDNEY NEOPLASMS; MOTHERS; MUTATION; NUCLEAR PROTEINS; ONCOGENE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; UBIQUITIN-PROTEIN LIGASES; WILMS TUMOR;

EID: 77950641105     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2890     Document Type: Article

References (48)

1. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 2006;15 Spec No 2:R196-201.
2. Koesters R, Ridder R, Kopp-Schneider A, et al. Mutational activation of the β-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 1999;59:3880-3882
3. Li CM, Kim CE, Margolin AA, et al. CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 2004;165:1943-1953
4. Maiti S, Alam R, Amos CI, Huff V. Frequent association of β-catenin and WT1 mutations in Wilms tumors. Cancer Res 2000;60:6288-6292
5. Royer-Pokora B, Weirich A, Schumacher V, et al. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein β1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology. Cancer 2008;113:1080-1089
6. Ruteshouser EC, Hendrickson BW, Colella S, Krahe R, Pinto L, Huff V. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors. Genes Chromosomes Cancer 2005;43:172-180
7. Rivera MN, Kim WJ, Wells J, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 2007;315:642-645
8. Ruteshouser EC, Robinson SM, Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 2008;47:461-470
9. Ogawa O, Eccles MR, Szeto J, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 1993; 362:749-751
10. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP. Relaxation of imprinted genes in human cancer. Nature 1993;362: 747-749
11. Scott RH, Stiller CA, Walker L, Rahman N. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet 2006;43:705-715
12. Bardeesy N, Falkoff D, Petruzzi MJ, et al. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 1994;7:91-97
13. Vujanic GM, Sandstedt B, Harms D, Kelsey A, Leuschner I, de Kraker J. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 2002;38:79-82.
14. Akhoondi S, Sun D, von der Lehr N, et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007;67:9006-9012
15. Schwab M, Alitalo K, Klempnauer KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305: 245-248
16. Fischer M, Spitz R, Oberthur A, Westermann F, Berthold F. Risk estimation of neuroblastoma patients using molecular markers. Klin Padiatr 2008;220:137-146
17. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 2005;17:7-13.
18. Lingjaerde OC, Baumbusch LO, Liestol K, Glad IK, Borresen-Dale AL. CGH-Explorer: a program for analysis of array-CGH data. Bioinformatics 2005;21:821-822
19. Beroukhim R, Lin M, Park Y, et al. Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol 2006;2:e41.
20. Corbin M, de Reynies A, Rickman DS, et al. WNT/β-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries? Genes Chromosomes Cancer 2009;48:816-827
21. Fukuzawa R, Heathcott RW, Sano M, Morison IM, Yun K, Reeve AE. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway. Pediatr Dev Pathol 2004;7:125-137
22. Schumacher V, Schneider S, Figge A, et al. Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci U S A 1997;94:3972-3977
23. Schumacher V, Schuhen S, Sonner S, et al. Two molecular subgroups of Wilms' tumors with or without WT1 mutations. Clin Cancer Res 2003;9:2005-2014
24. Austinat M, Dunsch R, Wittekind C, Tannapfel A, Gebhardt R, Gaunitz F. Correlation between β-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma. Mol Cancer 2008;7:21.
25. Haruta M, Arai Y, Sugawara W, et al. Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities. Genes Chromosomes Cancer 2008;47:712-727
26. Mao JH, Perez-Losada J, Wu D, et al. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 2004;432: 775-779
27. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008;8:83-93.
28. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453:110-114
29. Tosello V, Mansour MR, Barnes K, et al. WT1 mutations in T-ALL. Blood 2009;114:1038-1045
30. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-974
31. Yuan E, Li CM, Yamashiro DJ, et al. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Mol Cancer Res 2005; 3:493-502.
32. McQuaid S, O'Meara A. N-myc oncogene amplification in paediatric tumours. Ir J Med Sci 1990;159:172-174
33. Norris MD, Brian MJ, Vowels MR, Stewart BW. N-myc amplification in Wilms' tumor. Cancer Genet Cytogenet 1988;30:187-189
34. Schaub R, Burger A, Bausch D, Niggli FK, Schafer BW, Betts DR. Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors. Cancer Genet Cytogenet 2007;172:61-65
35. Williamson D, Lu YJ, Gordon T, et al. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol 2005;23: 880-888
36. Aldosari N, Bigner SH, Burger PC, et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 2002;126:540-544
37. Pfister S, Remke M, Benner A, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009;27:1627-1636
38. Lee WH, Murphree AL, Benedict WF. Expression and amplification of the N-myc gene in primary retinoblastoma. Nature 1984;309:458-460
39. Corson TW, Gallie BL. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer 2007;46:617-634
40. Nisen PD, Rich MA, Gloster E, et al. N-myc oncogene expression in histopathologically unrelated bilateral pediatric renal tumors. Cancer 1988;61:1821-1826
41. Shaw AP, Poirier V, Tyler S, Mott M, Berry J, Maitland NJ. Expression of the N-myc oncogene in Wilms' tumour and related tissues. Oncogene 1988;3:143-149
42. Williams RD, Hing SN, Greer BT, et al. Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. Genes Chromosomes Cancer 2004;41:65-79.
43. Wittmann S, Wunder C, Zirn B, et al. New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Genes Chromosomes Cancer 2008;47:386-395
44. Zirn B, Hartmann O, Samans B, et al. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int J Cancer 2006;118:1954-1962
45. Berrebi D, Leclerc J, Schleiermacher G, et al. High cyclin E staining index in blastemal, stromal or epithelial cells is correlated with tumor aggressiveness in patients with nephroblastoma. PLoS ONE 2008;3: e2216.
46. Otto T, Horn S, Brockmann M, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009; 15:67-78.
47. Tonini GP, Pistoia V. Molecularly guided therapy of neuroblastoma: a review of different approaches. Curr Pharm Des 2006;12:2303-2317
48. Browser tracks from http://genome.ucsc.edu.